Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Current Deferred Revenue (2021 - 2025)

Silo Pharma's Current Deferred Revenue history spans 5 years, with the latest figure at $72102.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed 0.0% year-over-year to $72102.0; the TTM value through Sep 2025 reached $72102.0, changed 0.0%, while the annual FY2024 figure was $72102.0, 2051.01% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $72102.0 at Silo Pharma, roughly flat from $72102.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.0 million in Q2 2021 and bottomed at $1676.0 in Q2 2023.
  • The 5-year median for Current Deferred Revenue is $72102.0 (2021), against an average of $309638.7.
  • The largest annual shift saw Current Deferred Revenue tumbled 99.84% in 2023 before it skyrocketed 4202.03% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $72102.0 in 2021, then changed by 0.0% to $72102.0 in 2022, then plummeted by 95.35% to $3352.0 in 2023, then soared by 2051.01% to $72102.0 in 2024, then changed by 0.0% to $72102.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Current Deferred Revenue are $72102.0 (Q3 2025), $72102.0 (Q2 2025), and $72102.0 (Q1 2025).